📝 What This Document Is 📄

This document is an SEC filing called a Schedule 14D-9. Think of it as a comprehensive, legally required informational packet provided to stockholders when a major corporate event, like a merger or acquisition, is proposed. 🚨 Since a deal was being discussed, the Soleno Board had to proactively tell investors exactly what was happening, why the deal was being recommended, and what the financial consequences would be.

👉 Why it matters: Because the filing is so long, it means the transaction is complex! It details not only the basic merger terms but also extensive information on executive payments, legal protections, and the entire history of negotiations.

🏢 What Soleno Therapeutics Does 🧬

Soleno Therapeutics is a biopharmaceutical company focused on drug development and commercialization. Its primary focus, and main source of revenue, is a drug called VYKAT XR. This medication is used in the United States to treat Prader-Willi Syndrome.

👉 In simple terms: Soleno's business model is simple but highly focused: develop and sell a specialized drug (VYKAT XR) that addresses a specific, serious genetic disorder. Its financial health is heavily dependent on the successful commercialization and regulatory status of this single product.

🏥 The Proposed Merger and Recommendation 🤝

The central theme of this filing is the proposed acquisition of Soleno by Neurocrine. The Board of Directors determined that accepting this acquisition would be in the best financial interest of Soleno’s stockholders.

• The Offer: The deal was solidified via a revised, "best and final" nonbinding proposal from Neurocrine. Under this final offer, Soleno’s shares would be purchased for $53.00 in cash per share.
• The Board's Action: The Soleno Board formally resolved to recommend that all stockholders accept the Offer and tender their shares to the purchasing company, Neurocrine.
• Why it matters: The Board's strong recommendation tells investors that, despite any personal conflicts or risks, they believe the $53.00 offer represents the highest value for the company at this time.

⏳ The Negotiation Timeline & Due Diligence 🛣️

The filing provides an extremely detailed, month-by-month account of the processes that led to the final $53.00 offer. This history shows that the company went through extensive evaluation before settling on the final deal.

• Initial Exploration (2025): Early negotiations included non-binding term sheets from three "Partnership Prospects" interested in licensing VYKAT XR outside the U.S. Later, a company called "Party A" submitted a nonbinding proposal for $86.00 per share (though this was never finalized).
• The Key Players: Other potential buyers, referred to as "Party C" and "Party D," also conducted due diligence but ultimately did not submit binding proposals.
• The Momentum Builds: The initial discussion with Neurocrine occurred on March 18, 2026, where the first nonbinding proposal was submitted for $50.00 per share.
• The Final Offer: After intensive due diligence and board review, Neurocrine submitted a "Final Neurocrine Proposal" on March 30, 2026, raising the price to $53.00 per share.
• Why it matters: The history shows that the Board continually used the competition and the high level of scrutiny from potential buyers to maximize value, culminating in the final price.

💰 Executive Compensation and Treatment of Shares 💲

When a merger happens, what happens to the money employees and directors are owed? This section details how Soleno's equity compensation and the leaders' payments will be handled.

• Shares and Options Cash-Out: All outstanding "In the Money Options" and "Company RSUs" (Restricted Stock Units) held by the 14 named officers and directors are slated to fully vest and be cashed out.
  • The total estimated merger consideration payable for these shares by the group of 14 officers and directors is $33,035,059 (from the combined table of cash amounts).
  • Impact: This means the merger provides a clear, cash-based payout for equity, simplifying the financial exit for the leadership.
• Severance and Golden Parachutes: The Board provides a massive table detailing the estimated payment upon a "qualifying termination" (a severance payout).
  • The total estimated cash payout (severance, bonus, etc.) for the 14 officers and directors is $33,035,059.
  • Definition: The filing explains that the "Golden Parachute" compensation relates to these substantial, guaranteed payments to executives in connection with a change in control.
• Executive Retention Program: Neurocrine has committed to a Neurocrine Retention Program that may award key employees up to $15,000,000 in aggregate.
  • Goal: This incentive aims to keep Soleno’s valuable personnel working for Neurocrine after the merger is complete.

⚖️ Protecting the Leaders and Company 🛡️

This filing dedicates significant space to ensuring that the current officers and directors are protected legally and financially, which is standard in major M&A deals.

• Indemnification and Insurance: The Merger Agreement guarantees that Neurocrine will honor and fulfill all previous indemnification and expense advancement provisions. For a period of six years after the deal closes, the surviving company must provide D&O (Directors & Officers) insurance coverage that is at least as favorable as what Soleno currently holds.
  • Why it matters: This provides peace of mind, protecting the leaders from legal costs and lawsuits that might arise before the merger was finalized.
• Supporting Stockholders: Anish Bhatnagar (CEO) and James Mackaness (former CFO) entered into Tender and Support Agreements with Neurocrine. Under these agreements, they committed to tendering all their shares and voting in favor of the merger.
  • Impact: This commitment provides stability and confidence to the market that the controlling stakeholders are fully committed to closing the deal.

📅 Next Steps and Commitments to Close 🏁

The filing meticulously lists the outstanding legal agreements and the timelines required to complete the acquisition.

• Merger Documentation: The final draft merger agreement and tender/support agreements were negotiated between March 31 and April 4, 2026, and are included as exhibits.
• Commitments: The Board is moving quickly to satisfy regulatory requirements (Rule 16b-3) by ensuring all director and executive stock dispositions are legally permitted.
• The Goal Date: Both Soleno and Neurocrine agreed to proceed with confirmation due diligence and negotiation with the aim of announcing the merger by April 6, 2026.

📎 Key Agreements and Contacts 📞

This section gathers the legal agreements, contact details, and foundational information needed for the reader to follow up.

• Confidentiality Agreements: The company executed confidentiality agreements with both Neurocrine and "Party D," which contained a "standstill" provision, meaning neither party could shop the company or make specific public statements about alternative deals for set periods.
• Employee Benefits: Neurocrine committed to maintaining salary and health/welfare benefits for continuing employees for at least one year post-merger, helping to ensure job stability and continuity.

🧠 The Analogy

Acquiring a company is like buying a prized, unique antique car. Before the sale, the seller (Soleno) must prove the car is worth a high price by letting many expert appraisers (the potential buyers/Party D) look at it. The buyers (Neurocrine) conduct their own deep inspection (due diligence) and, after a long negotiation period, they agree on a final price ($53/share) and a complex contract (the Merger Agreement) that details not only the payment but also who gets paid if the car breaks down afterward (severance/indemnity).

🧩 Final Takeaway

The Soleno Board has successfully navigated intense competitive pressure from multiple potential buyers to secure a favorable, cash-based acquisition offer of $53.00 per share from Neurocrine. The deal is structured with detailed provisions to protect the compensation and investments of key executives and directors, ensuring a clear exit for shareholders.